Cardiomyopathy, Dilated Clinical Trial
Official title:
Safeness and Effectiveness of Autologous Hematopoietic Cell Infusion Through Catheterization in Pediatric Patients With Dilated Cardiomyopathy
The purpose of this study is to determine whether an autologous stem cell infusion through
catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy.
Process:
1. Primary Evaluation
- Clinical History
- Echocardiogram to evaluate ejection fraction and other parameters
2. Signing of Informed Consent and clearing doubts
3. Bone Marrow stimulation for 3 consecutive days with G-CSF (Granulocyte Colony
Stimulating Factor) applied subcutaneously
4. On the 4th day, in operation room and under sedation: Bone Marrow Harvest performed by
hematologists through posterior iliac crests(amount calculated at 8cc/kg, without
exceeding 150ml).
5. Recovery room with family members while the cells are being processed in the Hematology
Laboratory.
6. Approximately 3 hours after the 1st procedure, the patient re-enters the operation
room, which is equipped for cardiac catheterization, so that cardiologists infuse the
stem cells through the femoral artery into the coronary arteries which irrigate the
heart´s muscle fibers.
7. Patient goes back to the recovery area until the anesthesia effect is gone and can
tolerate oral liquids.
8. Clinical and echocardiographic follow-ups at 6 weeks and 6 months after the procedure.
- The Patient will receive standard surgical care, accompanied by a nurse at all times.
- Premedication includes: Omeprazole (gastric protector), Ketorolac (anti-pain and
swelling), ondansetron (antivomiting).
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03560167 -
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
|
N/A | |
Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
Completed |
NCT00549861 -
Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR
|
N/A | |
Terminated |
NCT04222101 -
Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT02517814 -
Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy
|
N/A | |
Completed |
NCT01391507 -
Pilot Study of COR-1 in Heart Failure
|
Phase 2 | |
Completed |
NCT01940081 -
The Leiden Nonischemic Cardiomyopathy Study
|
||
Completed |
NCT01181414 -
Spanish Atrial Fibrillation And Resynchronization Study
|
Phase 4 | |
Not yet recruiting |
NCT06091475 -
Therapy to Maintain Remission in Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03340675 -
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
Recruiting |
NCT05981092 -
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease)
|
||
Not yet recruiting |
NCT06039072 -
Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function
|
||
Recruiting |
NCT03910725 -
Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death
|
||
Terminated |
NCT01478087 -
Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)
|
N/A | |
Recruiting |
NCT00221780 -
Role of Left Ventricular Pacing Site
|
N/A | |
Terminated |
NCT02958098 -
My Research Legacy Pilot Study
|
||
Completed |
NCT00123071 -
Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network
|
N/A | |
Completed |
NCT00284713 -
Progenitor Cell Therapy in Dilative Cardiomyopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01260402 -
Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.
|
N/A | |
Completed |
NCT04192214 -
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
|
Phase 2 |